ALLERGIC RHINITIS DRUGS MARKET FORECAST 2014-2024
Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines

世界のアレルギー性鼻炎治療薬市場予測:抗ヒスタミン剤、コルチコステロイド、免疫治療、ワクチン

◆タイトル:ALLERGIC RHINITIS DRUGS MARKET FORECAST 2014-2024
Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines
◆商品コード:VISG409043
◆調査・発行会社:visiongain
◆発行日:2014年8月
◆ページ数:274
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界のアレルギー性鼻炎治療薬市場予測:抗ヒスタミン剤、コルチコステロイド、免疫治療、ワクチン"について調査・分析し、レポートサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

Allergic rhinitis drugs – new study showing you trends, R&D progress, and predicted revenues
Where is the allergic rhinitis drugs market heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 274-page report provides 204 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of five exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
• Maureen Jenkins, Director of Clinical Services, Allergy UK
• Tonya Winders, President & CEO, Allergy and Asthma Network Mothers of Asthmatics (AANMA)
• Jonathan Bernstein, Professor, University of Cincinnati College of Medicine
• Hazel Econs, Financial & Marketing Director, Allergy Medical UK
• Kimihiro Okubo, Chairman and Professor, Nippon Medical School

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you will see forecasts to 2024 for these five submarkets:
• Oral antihistamines
• Intranasal corticosteroids
• Intranasal antihistamines
• Immunotherapy
• Other drugs.

Additionally, our new study provides global sales forecasts by volume for the intranasal corticosteroids and intranasal antihistamines submarkets, including individual global sales forecasts by volume for the leading drugs in these submarkets from 2014-2024.

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading drugs perform to 2024 at the world level? Our study forecasts sales of 26 products, including these brands:
• Nasonex
• Allegra/Allegra-D/Allegra OTC
• Zyrtec/Zyrtec D
• Claritin/Claritin OTC
• Astepro
• Avamys/Veramyst
• Xyzal
• Allelock
• Staloral
• Clarinex

Discover how high revenues can go. You will see what is happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2024:
• US
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• India
• Brazil
• Russia
• Mexico
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that India, China, Mexico and Brazil, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth
Overall world revenue for allergic rhinitis drugs will reach $11.3bn in 2014, our work forecasts. We predict revenue growth from 2014 to 2024. Rising demand for allergic rhinitis drugs, expanding healthcare coverage, economic recovery and the growth of the immunotherapy submarket will increase sales to 2024.

Our work shows you what organisations hold greatest potential. See profiles of 8 leading companies, including these:
• ALK-Abelló
• GSK
• Johnson & Johnson (J&J)
• Kyowa Hakko Kirin
• Merck & Co. (Merck)
• Sanofi
• Stallergenes
• UCB.

A company profile gives you the following information:
• Revenue forecast for allergic rhinitis drugs from 2014 to 2024
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

【レポートの目次】

1. Report Overview
1. Report Overview
1.1 Global Allergic Rhinitis Drugs Market Overview
1.2 Global Allergic Rhinitis Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Allergic Rhinitis
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 A Brief Overview of Allergy
2.3 Allergic Rhinitis
2.3.1 The Global Prevalence of Allergic Rhinitis
2.3.2 Pathophysiology of Allergic Rhinitis: IgEs and Mast Cells
2.3.3 Symptoms of Allergic Rhinitis
2.3.4 Classification of Allergic Rhinitis
2.3.4.1 Non-Allergic Rhinitis and Mixed Rhinitis
2.3.5 Seasonal Allergic Rhinitis (Hay Fever)
2.3.6 Perennial Allergic Rhinitis
2.3.7 Diagnosis of Allergic Rhinitis
2.4 Treatment of Allergic Rhinitis
2.4.1 Antihistamines
2.4.1.1 First-Generation Antihistamines
2.4.1.2 Second- and Third-Generation Antihistamines
2.4.2 Corticosteroids
2.4.2.1 First-, Second- and Third-Generation Intranasal Corticosteroids
2.4.2.2 Combination Drug Products
2.4.3 Leukotriene Receptor Antagonists
2.4.4 Cromolyn (cromoglicic acid)
2.4.5 Decongestants
2.4.6 Saline Nasal Sprays
2.4.7 Immunotherapy and Vaccines
2.5 Phases of Clinical Trials
2.6 Scope of this Report
2.7 Currency Exchange Rates in This Report

3. Allergic Rhinitis Drugs: World Market 2014-2024
3.1 The World Allergic Rhinitis Drugs Market in 2013
3.1.1 Leading Allergic Rhinitis Drugs
3.1.2 Leading Companies in the Allergic Rhinitis Drugs Market
3.2 World Allergic Rhinitis Drugs Market: Sales Forecast 2014-2024
3.3 Oral Antihistamines Lead the World Allergic Rhinitis Drugs Market
3.4 How Will Segmental Market Shares Change to 2024?
3.5 World Allergic Rhinitis Drugs Market: Drivers and Restraints 2014-2024

4. Leading National Allergic Rhinitis Drugs Markets 2014-2024
4.1 Geographical Breakdown of the World Allergic Rhinitis Drugs Market
4.2 World Allergic Rhinitis Drugs Market: National Markets Forecast 2014-2024
4.2.1 How Will National Market Shares Change to 2024?
4.3 The US Allergic Rhinitis Drugs Market 2014-2024
4.3.1 US Allergic Rhinitis Drugs Market Forecast 2014-2024
4.3.2 US Allergic Rhinitis Drugs Market: Trends and Developments
4.3.2.1 Rx-to-OTC Switching of Intranasal Corticosteroids
4.3.2.2 Affordable Care Act: Expanding Medicare Coverage
4.4 Chinese Allergic Rhinitis Drugs Market 2014-2024
4.4.1 Chinese Allergic Rhinitis Drugs Market Forecast 2014-2024
4.4.2 Chinese Allergic Rhinitis Drugs Market: Trends and Developments
4.4.2.1 Air Pollution Associated With Increasing Prevalence
4.4.2.2 Expansion of Healthcare Coverage and Reimbursement
4.5 Japanese Allergic Rhinitis Drugs Market 2014-2024
4.5.1 Japanese Allergic Rhinitis Drugs Market Forecast 2014-2024
4.5.2 Japanese Allergic Rhinitis Drugs Market: Trends and Developments
4.5.2.1 Cedar Reforestation and the Hay Fever Epidemic
4.5.2.2 Generic Penetration to Reach 60% by 2018?
4.5.2.3 Genetically Modified Rice as Immunotherapy
4.6 EU5 Allergic Rhinitis Drugs Market 2014-2024
4.6.1 German Allergic Rhinitis Drugs Market Forecast 2014-2024
4.6.2 French Allergic Rhinitis Drugs Market Forecast 2014-2024
4.6.3 UK Allergic Rhinitis Drugs Market Forecast 2014-2024
4.6.4 Italian Allergic Rhinitis Drugs Market Forecast 2014-2024
4.6.5 Spanish Allergic Rhinitis Drugs Market Forecast 2014-2024
4.6.6 EU5 Allergic Rhinitis Drugs Market: Trends and Developments
4.6.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.6.6.2 France: Social Security Finance Bill 2014
4.6.6.3 UK: Increasing Burden of Allergy
4.6.6.4 Italy: Austerity Measures Limiting Growth
4.6.6.5 Spain: The Start of Recovery in the Spanish Economy
4.7 Russian Allergic Rhinitis Drugs Market 2014-2024
4.7.1 Russian Allergic Rhinitis Drugs Market Forecast 2014-2024
4.7.2 Russian Allergic Rhinitis Drugs Market: Trends and Developments
4.7.2.1 Pharma2020 and the Russian Pharmaceutical Industry
4.8 Indian Allergic Rhinitis Drugs Market 2014-2024
4.8.1 Indian Allergic Rhinitis Drugs Market Forecast 2014-2024
4.8.2 Indian Allergic Rhinitis Drugs Market: Trends and Developments
4.8.2.1 Drug Prices Control Order 2013
4.8.2.2 Expansion of Healthcare Provision
4.9 Brazilian Allergic Rhinitis Drugs Market 2014-2024
4.9.1 Brazilian Allergic Rhinitis Drugs Market Forecast 2014-2024
4.9.2 Brazilian Allergic Rhinitis Drugs Market: Trends and Developments
4.9.2.1 Increasing Access to Medicines
4.10 Mexican Allergic Rhinitis Drugs Market 2014-2024
4.10.1 Mexican Allergic Rhinitis Drugs Market Forecast 2014-2024
4.10.2 Mexican Allergic Rhinitis Drugs Market: Trends and Developments
4.10.2.1 Seguro Popular: Mexican Healthcare Reform

5. Oral Antihistamines Market 2014-2024
5.1 Oral Antihistamines: A Market in Decline
5.2 Leading Oral Antihistamines in 2013
5.3 Oral Antihistamines: Market Forecast 2014-2024
5.4 Market Share of Leading Oral Antihistamines to 2024
5.5 Oral Antihistamines: Trends and Developments
5.5.1 Patent Expiry and Generic Competition
5.5.2 The Rx-to-OTC Rush
5.5.3 Combination Therapy with Intranasal Corticosteroids
5.6 Allegra/Allegra-D/Allegra OTC (fexofenadine, Sanofi)
5.6.1 Allegra/Allegra OTC: Sales Forecast 2014-2024
5.7 Zyrtec/Zyrtec D (cetirizine, Johnson & Johnson/UCB/GSK)
5.7.1 Zyrtec/Zyrtec D: Sales Forecast 2014-2024
5.8 Claritin/Claritin OTC (loratadine, Merck & Co.)
5.8.1 Claritin/Claritin OTC: Sales Forecast 2014-2024
5.9 Xyzal (levocetirizine, Sanofi/UCB/GSK)
5.9.1 Xyzal: Sales Forecast 2014-2024
5.10 Allelock (olopatadine, Kyowa Hakko Kirin)
5.10.1 Allelock: Sales Forecast 2014-2024
5.11 Clarinex (desloratadine, Merck & Co.)
5.11.1 Clarinex: Sales Forecast 2014-2024
5.12 Talion (bepotastine, Mitsubishi Tanabe)
5.12.1 Talion: Sales Forecast 2014-2024
5.13 Ebastel (ebastine, Almirall/Takeda/Dainippon Sumitomo)
5.13.1 Ebastel: Sales Forecast 2014-2024
5.14 Other Oral Antihistamines

6. Intranasal Corticosteroids Market 2014-2024
6.1 Intranasal Corticosteroids: First-line for Allergic Rhinitis
6.2 Leading Intranasal Corticosteroids in 2013
6.3 Intranasal Corticosteroids: Market Forecast by Value, 2014-2024
6.4 Intranasal Corticosteroids: Market Forecast by Volume, 2014-2024
6.5 Market Share of Leading Intranasal Corticosteroids to 2024
6.6 Intranasal Corticosteroids: Trends and Developments
6.6.1 Nasonex Patent Expiry in 2014
6.6.2 Nasacort AQ Switched to OTC
6.7 Nasonex (mometasone, Merck)
6.7.1 Nasonex: Sales Forecast by Value, 2014-2024)
6.7.2 Nasonex: Sales Forecast by Volume, 2014-2024)
6.8 Avamys/Veramyst (fluticasone furoate, GSK)
6.8.1 Avamys/Veramyst: Sales Forecast by Value, 2014-2024)
6.8.2 Avamys/Veramyst: Sales Forecast by Volume, 2014-2024)
6.9 Flixonase/Flonase (fluticasone propionate, GSK)
6.9.1 Flixonase/Flonase: Sales Forecast by Value, 2014-2024)
6.9.2 Flixonase/Flonase: Sales Forecast by Volume, 2014-2024)
6.10 Rhinocort (budesonide, AstraZeneca)
6.10.1 Rhinocort: Sales Forecast by Value, 2014-2024)
6.10.2 Rhinocort: Sales Forecast by Volume, 2014-2024)
6.11 Omnaris (ciclesonide, Dainippon Sumitomo/Takeda)
6.11.1 Omnaris: Sales Forecast by Value, 2014-2024)
6.11.2 Omnaris: Sales Forecast by Volume, 2014-2024)
6.12 Beconase/Beconase AQ (beclometasone, GSK/Omega Pharma)
6.12.1 Beconase/Beconase AQ: Sales Forecast by Value, 2014-2024)
6.12.2 Beconase/Beconase AQ: Sales Forecast by Volume, 2014-2024)
6.13 Nasacort (triamcinolone, Sanofi)
6.13.1 Nasacort: Sales Forecast by Value, 2014-2024)
6.13.2 Nasacort: Sales Forecast by Volume, 2014-2024)
6.14 QNasl (beclometasone, Teva)
6.14.1 QNasl: Sales Forecast by Value, 2014-2024)
6.14.2 QNasl: Sales Forecast by Volume, 2014-2024)
6.15 Zetonna (ciclesonide, Dainippon Sumitomo)
6.15.1 Zetonna: Sales Forecast by Value, 2014-2024)
6.15.2 Zetonna: Sales Forecast by Volume, 2014-2024)
6.16 Generic Intranasal Corticosteroids
6.16.1 Generic Intranasal Beclometasone
6.16.1.1 Generic Intranasal Beclometasone: Sales Forecast by Value, 2014-2024
6.16.1.2 Generic Intranasal Beclometasone: Sales Forecast by Volume, 2014-2024
6.16.2 Generic Intranasal Budesonide
6.16.2.1 Generic Intranasal Budesonide: Sales Forecast by Value, 2014-2024
6.16.2.2 Generic Intranasal Budesonide: Sales Forecast by Volume, 2014-2024
6.16.3 Generic Intranasal Flunisolide
6.16.3.1 Generic Intranasal Flunisolide: Sales Forecast by Value, 2014-2024
6.16.3.2 Generic Intranasal Flunisolide: Sales Forecast by Volume, 2014-2024
6.16.4 Generic Intranasal Fluticasone
6.16.4.1 Generic Intranasal Fluticasone: Sales Forecast by Value, 2014-2024
6.16.4.2 Generic Intranasal Fluticasone: Sales Forecast by Volume, 2014-2024
6.16.5 Generic Intranasal Mometasone
6.16.5.1 Generic Intranasal Mometasone: Sales Forecast by Value, 2014-2024
6.16.5.2 Generic Intranasal Mometasone: Sales Forecast by Volume, 2014-2024
6.16.6 Generic Intranasal Triamcinolone
6.16.6.1 Generic Intranasal Triamcinolone: Sales Forecast by Value, 2014-2024
6.16.6.2 Generic Intranasal Triamcinolone: Sales Forecast by Volume, 2014-2024

7. Intranasal Antihistamines Market 2014-2024
7.1 Intranasal Antihistamines: A Niche Segment
7.2 Leading Intranasal Antihistamines in 2013
7.3 Intranasal Antihistamines: Market Forecast by Value, 2014-2024
7.4 Intranasal Antihistamines: Market Forecast by Volume, 2014-2024
7.5 Market Share of Leading Intranasal Antihistamines to 2024
7.6 Intranasal Antihistamines: Trends and Developments
7.6.1 Azelastine versus Olopatadine
7.6.2 Intranasal Combination Products
7.7 Astepro (azelastine, Meda)
7.7.1 Astepro: Sales Forecast 2014-2024
7.8 Patanase (olopatadine, Novartis)
7.8.1 Patanase: Sales Forecast 2014-2024
7.9 Astelin (azelastine, Meda)
7.9.1 Astelin: Sales Forecast 2014-2024
7.10 Dymista (azelastine/fluticasone, Meda)
7.10.1 Dymista: Sales Forecast 2014-2024
7.11 Generic Intranasal Azelastine
7.11.1 Generic Intranasal Azelastine: Sales Forecast by Value, 2014-2024
7.11.1 Generic Intranasal Azelastine: Sales Forecast by Volume, 2014-2024
7.12 Generic Intranasal Olopatadine
7.12.1 Generic Intranasal Azelastine: Sales Forecast by Value, 2014-2024
7.12.2 Generic Intranasal Azelastine: Sales Forecast by Volume, 2014-2024

8. Immunotherapy and Vaccines Market 2014-2024
8.1 Immunotherapy: Set for Rapid Expansion
8.2 Leading Immunotherapy Products in 2013
8.3 Immunotherapy: Market Forecast 2014-2024
8.4 Market Share of Leading Immunotherapy Products to 2024
8.5 Immunotherapy: Leading Companies
8.6 Immunotherapy: Trends and Developments
8.6.1 Subcutaneous and Sublingual Immunotherapy
8.6.2 Expansion into the US Market
8.6.3 Standardisation of Immunotherapy Products
8.6.4 Immunotherapy as a Preventative Treatment
8.7 Staloral (Grass pollen allergen extract, Stallergenes)
8.7.1 Staloral: Sales Forecast 2014-2024
8.8 Alutard SQ (Grass pollen allergen extract, ALK-Abelló)
8.8.1 Alutard SQ: Sales Forecast 2014-2024
8.9 Grazax/Grastek (Timothy grass pollen allergen extract, ALK-Abelló/Merck)
8.9.1 Grazax/Grastek: Sales Forecast 2014-2024
8.10 Oralair (Grass pollen allergen extract, Stallergenes/Greer)
8.10.1 Oralair: Sales Forecast 2014-2024
8.11 Ragwitek (Short ragweed pollen allergen extract, Merck)
8.11.1 Ragwitek: Sales Forecast 2014-2024

9. Leading Companies in the Allergic Rhinitis Drugs Market in 2014
9.1 Allergic Rhinitis Drugs: Merck & Co. Leads in a Fragmented Market
9.2 ALK-Abelló
9.2.1 ALK-Abelló: Allergic Rhinitis Drugs
9.2.2 ALK-Abelló: Allergic Rhinitis Sales Forecast 2014-2024
9.2.3 ALK-Abelló: Products in Development
9.2.4 ALK-Abelló: Recent Developments
9.2.4.1 ALK Collaborates with EddingPharm to Boost China Sales
9.2.4.2 Jext Product Recall
9.3 GSK
9.3.1 GSK: Allergic Rhinitis Drugs
9.3.2 GSK: Allergic Rhinitis Sales Forecast 2014-2024
9.3.3 GSK: Products in Development
9.3.4 GSK: Recent Developments
9.3.4.1 GSK Divestment of OTC Products
9.3.4.2 GSK Asset Swap with Novartis to Restructure Consumer Health
9.4 Johnson & Johnson
9.4.1 Johnson & Johnson: Allergic Rhinitis Drugs
9.4.2 Johnson & Johnson: Allergic Rhinitis Sales Forecast 2014-2024
9.4.3 Johnson & Johnson: Recent Developments
9.4.3.1 Launch of Zyrtec Dissolve Tabs
9.4.3.2 Manufacturing Recalls at McNeil Consumer Healthcare
9.5 Kyowa Hakko Kirin
9.5.1 Kyowa Hakko Kirin: Allergic Rhinitis Drugs
9.5.2 Kyowa Hakko Kirin: Allergic Rhinitis Sales Forecast 2014-2024
9.6 Merck & Co.
9.6.1 Merck: Allergic Rhinitis Drugs
9.6.2 Merck: Allergic Rhinitis Sales Forecast 2014-2024
9.6.3 Merck: Products in Development
9.6.4 Merck: Recent Developments
9.6.4.1 Bayer Acquires Merck’s Consumer Health Business
9.6.4.2 FDA Rejects Singulair OTC Switch
9.7 Sanofi
9.7.1 Sanofi: Allergic Rhinitis Drugs
9.7.2 Sanofi: Allergic Rhinitis Sales Forecast 2014-2024
9.8 Stallergenes
9.8.1 Stallergenes: Allergic Rhinitis Drugs
9.8.2 Stallergenes: Allergic Rhinitis Sales Forecast 2014-2024
9.8.3 Stallergenes: Products in Development
9.8.4 Stallergenes: Recent Developments
9.8.4.1 Stallergenes Acquires Argentinean Company Alergo Pharma
9.8.4.2 Greer launches Oralair in the US
9.9 UCB
9.9.1 UCB: Allergic Rhinitis Drugs
9.9.2 UCB: Allergic Rhinitis Sales Forecast 2014-2024
9.10 Other Leading Companies

10. Allergic Rhinitis Drugs Pipeline Analysis 2014-2024
10.1 Trends and Developments in the Allergic Rhinitis Pipeline
10.2 The Oral Antihistamine Pipeline
10.2.1 Talion (bepotastine, Mitsubishi Tanabe)
10.2.2 ZPL-3893787 (histamine H4R antagonist, Ziarco Pharma)
10.2.3 ZPL-868087 (oral histamine H3R antagonist, Ziarco Pharma)
10.3 The Intranasal Corticosteroids Pipeline
10.3.1 APC-3000 (HFA inhaled corticosteroid, Adamis Pharmaceuticals)
10.3.2 S0597 (topical glucocorticoid, Sun Pharma)
10.3.3 TBS-6 (Trimel Pharmaceuticals)
10.4 The Immunotherapy Pipeline
10.4.1 Actair (house dust mite SLIT, Stallergenes/Shionogi)
10.4.2 AllerT (subcutaneous birch pollen immunotherapy, Anergis)
10.4.3 Cat-SPIRE and other -SPIRE Therapies (synthetic peptide immunoregulatory epitopes, Circassia)
10.4.4 Depigoid Birch 5000 (birch pollen allergen extract, Leti Pharma)
10.4.5 House Dust Mite SLIT-Tablet (MK-8237, ALK-Abelló/Merck/Torii)
10.4.6 Pollinex Quattro (subcutaneous immunotherapies, Allergy Therapeutics)
10.4.7 gp-ASIT+ (grass pollen allergen fragments, Biotech Tools)
10.4.8 Betula verrucosa (Bet v) 1 allergen (Stallergenes)
10.5 The Pipeline for Other Allergic Rhinitis Drugs
10.5.1 eN-Lac (Lactobacillus paracasei GMNL-32, GenMont Biotech)
10.5.2 S-555739 (prostaglandin D2 receptor antagonist, Shionogi)
10.5.3 DSP-3025/AZD-8848 (toll-like receptor 7 agonist, Dainippon Sumitomo/AstraZeneca)
10.5.4 GSK2245035 (toll-like receptor 7 agonist, GSK)
10.5.5 HP-3060 (transdermal long-acting tape, Hisamitsu)
10.5.6 MRX-4 (anti-inflammatory agent, Celsus Therapeutics)
10.5.7 OC459 (Oxagen/Atopix Therapeutics/Eleventa)
10.5.8 ONO-4053 (prostaglandin D2 receptor antagonist, Ono Pharmaceutical)
10.5.9 WF10 (tetrachlorodecaoxygen chlorite matrix, Nuvo Research)
10.5.10 RPL554 (PDE-3/PDE-4 antagonist, Verona Pharma)
10.5.11 VTX-1463 (toll-like receptor 8 agonist, VentiRx)

11. Qualitative Analysis of the Allergic Rhinitis Drugs Market 2014-2024
11.1 SWOT Analysis of the Allergic Rhinitis Drugs Market
11.2 Strengths
11.2.1 High Unmet Clinical Need
11.2.2 Established Role of Allergic Rhinitis Drugs in Treatment
11.2.3 High Profile Disease Encouraging Improving Healthcare Provision
11.2.4 Increasing Consumer Demand
11.3 Weaknesses
11.3.1 Increasing Generic Penetration
11.3.2 Patient Dissatisfaction with Intranasal Corticosteroids
11.3.3 Limited Allergic Rhinitis Drugs Pipeline
11.4 Opportunities
11.4.1 The Rise of Immunotherapy
11.4.2 Higher Growth in Emerging Markets
11.4.3 Combination Drug Products
11.4.4 Rx-to-OTC Switching
11.5 Threats
11.5.1 Patent Expiry
11.5.2 Cost-Containment
11.5.3 Rising API and Manufacturing Costs
11.6 Porter’s Five Forces Analysis of the Allergic Rhinitis Drugs Market
11.6.1 Rivalry Among Competitors [High]
11.6.2 Threat of New Entrants [Low]
11.6.3 Power of Suppliers [Low]
11.6.4 Power of Buyers [Medium]
11.6.5 Threat of Substitutes [Low]

12. Research Interviews
12.1 Interview with Maureen Jenkins, Director of Clinical Services for Allergy UK, Sidcup, Kent, UK
12.1.1 Allergic Rhinitis in the UK
12.1.2 Allergic Rhinitis Treatments
12.1.3 Opportunities for Manufacturers
12.2 Interview with Kimihiro Okubo, Chairman and Professor, Department of Otolaryngology, Nippon Medical School, Tokyo, Japan
12.2.1 Allergic Rhinitis in Japan
12.3 Interview with Jonathan Bernstein, Chairman and Professor, Department of Internal Medicine, University of Cincinnati, Ohio, US
12.3.1 Allergic Rhinitis in the US
12.3.2 Nasacort AQ and OTC Nasal Sprays
12.3.3 Dymista and Combination Therapies
12.3.4 Trends and Developments in Allergic Rhinitis
12.4 Interview with Tonya Winders, President and CEO, Allergy & Asthma Network Mothers of Asthmatics, Virginia, US
12.4.1 Allergic Rhinitis in the US
12.4.2 Allergic Rhinitis Treatments
12.4.3 US Healthcare Reform and Intranasal Drugs
12.5 Interview with Allergy Medical UK, Weybridge, UK
12.5.1 Allergic Rhinitis Treatments

13. Conclusions
13.1 Allergic Rhinitis Drugs: A Mature Market
13.2 The World Allergic Rhinitis Market in 2013
13.2.1 Current Leading Allergic Rhinitis Segments
13.2.2 Leading Allergic Rhinitis Products
13.2.3 Leading Allergic Rhinitis Drugs Companies
13.2.4 Leading National Markets
13.3 World Allergic Rhinitis Drugs Market Forecast 2014-2024
13.4 Allergic Rhinitis Late-Stage Pipeline
13.5 The Future of the Allergic Rhinitis Drugs Market?



List of Tables
Table 1.1 Leading National Allergic Rhinitis Drugs Market Forecast 2014 ($m, AGR%)
Table 2.1 Leading Antihistamines for Allergic Rhinitis, 2014
Table 2.2 Leading Corticosteroids for Allergic Rhinitis, 2014
Table 2.3 Clinical Trial Phases
Table 2.4 Currency Exchange Rates, 2013
Table 3.1 Top 10 Allergic Rhinitis Drugs: Revenue ($m), 2013
Table 3.2 Top 10 Allergic Rhinitis Drug Manufacturers: Allergic Rhinitis Drugs Revenue ($m), Market Share (%), 2013
Table 3.3 World Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 3.4 Market Shares (%) of Leading Allergic Rhinitis Drugs Market Segments, 2013, 2018 and 2024
Table 4.1 World Allergic Rhinitis Drugs Market Forecast: Revenues ($m) and Market Shares (%) by National Market, 2013
Table 4.2 World Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by National Market, 2013-2024
Table 4.3 Market Shares (%) of Leading National Allergic Rhinitis Drugs Markets, 2013, 2018 and 2024
Table 4.4 US Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.5 Chinese Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.6 Japanese Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.7 EU5 Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by National Market, 2013-2024
Table 4.8 German Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.9 French Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.10 UK Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.11 Italian Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.12 Spanish Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.13 Russian Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.14 Indian Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.15 Brazilian Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.16 Mexican Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 5.1 Leading Oral Antihistamines: Revenues ($m) and Market Shares (%), 2013
Table 5.2 Oral Antihistamines Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 5.3 Oral Antihistamines Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 5.4 Sanofi: Allegra/Allegra-D/Allegra OTC Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.5 Johnson & Johnson/UCB/GSK: Zyrtec/Zyrtec-D Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.6 Merck: Claritin/Claritin OTC Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.7 Sanofi/UCB/GSK: Xyzal Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.8 Kyowa Hakko Kirin: Allelock Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.9 Merck: Clarinex Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.10 Mitsubishi Tanabe: Talion Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.11 Almirall/Dainippon Sumitomo/Takeda: Ebastel Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.1 Leading Intranasal Corticosteroids: Revenues ($m) and Market Shares (%), 2013
Table 6.2 Intranasal Corticosteroids Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 6.3 Intranasal Corticosteroids Market Forecast by Volume: Sprays (million), AGR (%), CAGR (%) by Drug, 2013-2024
Table 6.4 Intranasal Corticosteroids Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 6.5 Merck: Nasonex Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.6 Merck: Nasonex Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.7 GSK: Avamys/Veramyst Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.8 GSK: Avamys/Veramyst Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.9 GSK: Flixonase/Flonase Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.10 GSK: Flixonase/Flonase Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.11 AstraZeneca: Rhinocort Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.12 AstraZeneca: Rhinocort Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.13 Dainippon Sumitomo/Takeda: Omnaris Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.14 Dainippon Sumitomo/Takeda: Omnaris Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.15 GSK/Omega Pharma: Beconase/Beconase AQ Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.16 GSK/Omega Pharma: Beconase/Beconase AQ Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.17 Sanofi: Nasacort Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.18 Sanofi: Nasacort Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.19 Teva: QNasl Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.20 Teva: QNasl Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.21 Dainippon Sumitomo: Zetonna Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.22 Dainippon Sumitomo: Zetonna Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.23 Generic Intranasal Beclometasone Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.24 Generic Intranasal Beclometasone Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.25 Generic Intranasal Budesonide Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.26 Generic Intranasal Budesonide Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.27 Generic Intranasal Flunisolide Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.28 Generic Intranasal Flunisolide Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.29 Generic Intranasal Fluticasone Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.30 Generic Intranasal Fluticasone Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.31 Generic Intranasal Mometasone Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.32 Generic Intranasal Mometasone Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 6.33 Generic Intranasal Triamcinolone Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.34 Generic Intranasal Triamcinolone Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 7.1 Intranasal Antihistamines Market Forecast by Value: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 7.2 Intranasal Antihistamines Market Forecast by Volume: Sprays (million), AGR (%), CAGR (%) by Drug, 2013-2024
Table 7.3 Intranasal Antihistamines Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 7.4 Meda: Astepro Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.5 Novartis: Patanase Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.6 Meda: Astelin Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.7 Meda: Dymista Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.8 Generic Intranasal Azelastine Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.9 Generic Intranasal Azelastine Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 7.10 Generic Intranasal Olopatadine Sales Forecast by Value: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.11 Generic Intranasal Olopatadine Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024
Table 8.1 Leading Immunotherapy Products: Revenues ($m) and Market Shares (%), 2013
Table 8.2 Immunotherapy Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Product, 2013-2024
Table 8.3 Immunotherapy Market: Market Shares (%) by Product, 2013, 2018 and 2024
Table 8.4 Leading Immunotherapy Companies: Immunotherapy Revenue ($m) and Market Share (%), 2013
Table 8.5 Stallergenes: Staloral Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.6 ALK-Abelló: Alutard SQ Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.7 ALK-Abelló/Merck: Grazax/Grastek Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.8 Stallergenes/Greer: Oralair Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.9 Merck: Ragwitek Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.1 ALK-Abelló: Overview, 2014
Table 9.2 ALK-Abelló: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.3 GSK: Overview, 2014
Table 9.4 GSK: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.5 Johnson & Johnson: Overview, 2014
Table 9.6 Johnson & Johnson: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.7 Kyowa Hakko Kirin: Overview, 2014
Table 9.8 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.9 Merck & Co.: Overview, 2014
Table 9.10 Merck: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.11 Sanofi: Overview, 2014
Table 9.12 Sanofi: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.13 Stallergenes: Overview, 2014
Table 9.14 Stallergenes: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.15 UCB: Overview, 2014
Table 9.16 UCB: Allergic Rhinitis Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 10.1 Allergic Rhinitis: Oral Antihistamines Pipeline, 2014
Table 10.2 Allergic Rhinitis: Intranasal Corticosteroids Pipeline, 2014
Table 10.3 Allergic Rhinitis: Immunotherapy Pipeline, 2014
Table 10.4 Allergic Rhinitis: Other Drugs Pipeline, 2014
Table 11.1 SWOT Analysis of the Allergic Rhinitis Drugs Market, 2014-2024
Table 13.1 Allergic Rhinitis Drugs Late-Stage Pipeline, 2014

★調査レポート[世界のアレルギー性鼻炎治療薬市場予測:抗ヒスタミン剤、コルチコステロイド、免疫治療、ワクチン] ( ALLERGIC RHINITIS DRUGS MARKET FORECAST 2014-2024
Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines / VISG409043) 販売に関する免責事項
[世界のアレルギー性鼻炎治療薬市場予測:抗ヒスタミン剤、コルチコステロイド、免疫治療、ワクチン] ( ALLERGIC RHINITIS DRUGS MARKET FORECAST 2014-2024
Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines / VISG409043) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆